Testing an immunotherapy combo before surgery for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (paclitaxel and cisplatin) before surgery can help shrink cervical cancer. It is for people with certain stages of cervical cancer who are candidates for surgery, including those who want to preserve their fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer of a specific type: squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- Your cancer is at a stage where surgery is planned. There are two groups: one for locally advanced cancer (tumors 4 cm or larger) and one for people who want to preserve fertility (tumors up to 6 cm).
- You are between 18 and 75 years old (or 18 to 45 if you wish to preserve fertility).
- You have not received immunotherapy before.
- You have good organ function and are not pregnant or breastfeeding.
- You agree to use effective contraception during the study and for 6 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug called Ivonescimab to standard chemotherapy (paclitaxel and cisplatin) given before a hysterectomy in women with cervical cancer stage IB2 or IIA1 (tumor size 2-4 cm). The goal is to see if this combination improves outcomes compared to chemo alone.
This trial tests if giving immunotherapy with chemotherapy before surgery can shrink tumors in people with advanced cervical cancer. It is for those who have not had any prior treatment.
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
Hear when a new Cervical Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.